|
As part of building up its biodefense portfolio, Bavarian Nordic has initiated a preclinical programme for an anthrax vaccine. The Company sees a number of synergies – both in the development and in market approach which support the development of such a vaccine. Also, it is expected that a combined anthrax and smallpox vaccine can be developed and thus Bavarian Nordic would be able to offer one vaccine against two of the top biological threats. The anthrax programme is expected to enter Phase I in 2008.
|
